Pre-made Simtuzumab benchmark antibody ( Whole mAb, anti-LOXL2 therapeutic antibody, Anti-LOR/LOR2/WS9-14 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Simtuzumab biosimilar, Whole mAb, Anti-LOXL2 Antibody: Anti-LOR/LOR2/WS9-14 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Simtuzumab (INN; formerly GS 6624) is a humanized monoclonal antibody designed for the treatment of fibrosis. It binds to LOXL2 and acts as an immunomodulator. In January 2016, Gilead Sciences terminated its Phase 2 clinical study in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-522-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Simtuzumab biosimilar, Whole mAb, Anti-LOXL2 Antibody: Anti-LOR/LOR2/WS9-14 therapeutic antibody
INN Name	Simtuzumab
Target	LOXL2
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2012
Year Recommended	2013
Companies	Arresto Biosciences;Gilead Sciences
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Colorectal cancer;Hepatic fibrosis;Idiopathic pulmonary fibrosis;Liver cirrhosis;Myelofibrosis;Non-alcoholic steatohepatitis;Pancreatic cancer;Primary sclerosing cholangitis
Development Tech	na